Download program (here)

May 31st, 2011

Session 1 (13.30-15.30): Anaphylaxis versus acute infusion reactions provoked by therapeutic antibodies

 Philippe Solal-Céligny (Le Mans, France). Infusion-related syndromes induced by monoclonals in onco-haematology

 Enrico Maggi (Florence, Italy). Acute infusion reactions induced by monoclonals

 Robin Thorpe (Biotherapeutics Group, , Hertfordshire, UK). Cytokine storms: the TGN1412 case

 Aurélie Grandvuillemin (Dijon, France). Clinical manifestations and incidence of anaphylactic events during cetuximab treatment in France


Charles Richet lecture (15:30-16:15):

 Thomas Platts-Mills (Charlottesville, USA). Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose




Session 2 (16:45-18:45): Glycans as targets of IgE and other natural antibodies, and their involvement in adverse reactions to therapeutic antibodies

 Uri Galili (Worcester, USA) The natural anti-Gal antibody in evolution and in the clinic

Yoann Pointreau (Tours,France). Factors influencing the production of anti-alphaGal IgE antibodies

Jean-François Bouhours (Nantes, France). The “Hanganutziu-Deicher antigen”: a historical perspective

Ajit Varki (San Diego,USA). Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic antibodies


Gala dinner in the Château of Villandry. The recent history of this famous castle in the Loire Valley is linked to Charles Richet 


June 1st, 2011

Session 3 (9:00-12:00): Strategies to prevent cetuximab anaphylaxis in clinical practice

 Roy Jefferis (Birmingham, UK). Cetuximab glycosylation

 Steffen Goletz (Glycotope, Heidelberg, Germany). Development of CetuGEX™, a cetuximab “biobetter”

 Johannes Blatter (Merck, Darmstadt, Germany). Premedication strategies to limit anaphylaxis to cetuximab




 Anne Moneret-Vautrin (Epinal,France). Skin testing to cetuximab

Anita Kober (Phadia, Uppsala, Sweden). New assays for the detection of anti-glycan IgE

Benoît Dupont (Caen, France). Predictive value of anti-cetuximab IgE antibodies 

Maya Jerath (Chapel Hill, USA). Desensitization to cetuximab



Final discussion, conclusion and end of meeting









This post is also available in: French

Comments are closed.